Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Protein degraders enter the clinic — a new approach to cancer therapy
Deborah Chirnomas, Keith R. Hornberger, Craig M. Crews
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 265-278
Closed Access | Times Cited: 284

Showing 1-25 of 284 citing articles:

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xin Xie, Tingting Yu, Xiang Li, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 104
Recent Progress of Supramolecular Chemotherapy Based on Host–Guest Interactions
Miaomiao Yan, Sha Wu, Yuhao Wang, et al.
Advanced Materials (2023) Vol. 36, Iss. 21
Closed Access | Times Cited: 78
Proximity-Based Modalities for Biology and Medicine
Xingui Liu, Alessio Ciulli
ACS Central Science (2023) Vol. 9, Iss. 7, pp. 1269-1284
Open Access | Times Cited: 73
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 56
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 44
Translating p53-based therapies for cancer into the clinic
Sylvain Peuget, Xiaolei Zhou, Galina Selivanova
Nature reviews. Cancer (2024) Vol. 24, Iss. 3, pp. 192-215
Closed Access | Times Cited: 39
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 33
Targeting cancer with small-molecule pan-KRAS degraders
Johannes Popow, William Farnaby, Andreas Gollner, et al.
Science (2024) Vol. 385, Iss. 6715, pp. 1338-1347
Open Access | Times Cited: 21
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
Christopher M. Hickey, Katherine M. Digianantonio, Kurt Zimmermann, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 2, pp. 311-322
Closed Access | Times Cited: 19
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 15
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 13
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression
Zhixiang Chen, Mi Wang, Dimin Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5275-5304
Closed Access | Times Cited: 13
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 32
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, et al.
Science Bulletin (2023) Vol. 68, Iss. 10, pp. 1069-1085
Closed Access | Times Cited: 31
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
Laurie P. Volak, Heide Marika Duevel, Sara C. Humphreys, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 792-803
Closed Access | Times Cited: 27
Clinical Translation of Targeted Protein Degraders
Nikki R. Kong, Lyn H. Jones
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 3, pp. 558-568
Closed Access | Times Cited: 26
Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies
Xingyu Wang, Benoı̂t Gigant, Xi Zheng, et al.
MedComm – Oncology (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 25
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 20
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Zonghui Ma, Andrew A. Bolinger, Haiying Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10991-11026
Open Access | Times Cited: 20
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
Stephen H. Norris, Xiaochu Ba, Jayce Rhodes, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16388-16409
Closed Access | Times Cited: 20
The variant landscape and function of DDX3X in cancer and neurodevelopmental disorders
Margaret Gadek, Elliott H. Sherr, Stephen N. Floor
Trends in Molecular Medicine (2023) Vol. 29, Iss. 9, pp. 726-739
Open Access | Times Cited: 19
Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma
Qi Chang, Jiayi Li, Yue Deng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2466-2486
Closed Access | Times Cited: 10
Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2
Deborah Grifagni, Elena Lenci, Alessia De Santis, et al.
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 2, pp. 250-257
Closed Access | Times Cited: 9
A PROTAC Augmenter for Photo‐Driven Pyroptosis in Breast Cancer
Daipeng Huang, Yang Zou, Haiqiao Huang, et al.
Advanced Materials (2024) Vol. 36, Iss. 21
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top